M.J. Biopharm
Biosimilar developer, India. 2 development products across 2 molecules: insulin glargine, insulin human.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Insulin glargine | M.J. Biopharm insulin glargine | · | · | · | · | · | Mar 2024 | · | 1/7 |
| Insulin human | M.J. Biopharm human insulin | · | · | · | · | · | Jun 2018 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with M.J. Biopharm, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOJun 2018MJ Biopharm (INN only), insulin human
- CDSCOMar 2024M.J. Biopharm (INN only), insulin glargine
Compare M.J. Biopharm with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant